FDA approves hepcidin mimetic for PV - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves hepcidin mimetic for PV

Phase 3 VERIFY results showed a 77% clinical response rate during weeks 20 to 32.

  • By

  • Kathryn Wighton

  • August 31, 2026

  • 3 min

Share

Clinical Scorecard: FDA approves hepcidin mimetic for PV

At a Glance

CategoryDetail
ConditionPolycythemia Vera
Key MechanismsRegulates iron distribution and red blood cell overproduction
Target PopulationAdults with erythrocytosis due to polycythemia vera
Care SettingOncology/Hematology

Key Highlights

  • Rusfertide (MIMRYLO) received FDA approval for treating erythrocytosis in polycythemia vera.
  • 77% of patients on rusfertide plus standard of care achieved a clinical response during weeks 20 to 32.
  • Common adverse reactions include injection-site reactions (56%) and anemia (16%).
  • Warnings include new or worsening thrombocytosis and embryo-fetal toxicity.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of polycythemia vera based on clinical and laboratory criteria.

Management

  • Treatment may include phlebotomy, hydroxyurea, interferon, and/or ruxolitinib.

Monitoring & Follow-up

  • Monitor hematocrit levels to maintain below 45%.

Risks

  • Increased risk of thrombotic events due to elevated hematocrit.

Patient & Prescribing Data

Patients with uncontrolled hematocrit dependent on phlebotomy.

Rusfertide is administered once weekly by subcutaneous injection.

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    FDA approves hepcidin mimetic for PV

    • by Kathryn Wighton

    • August 31, 2026

    Related Content

    Photodynamic therapy gains FDA approval for superficial BCC

    Phase 3 trial data showed greater clinical and histological clearance than with placebo photodynamic therapy.

    Social vulnerability may contribute to disparities in ovarian cancer survival

    Neighborhood vulnerability was associated with poorer survival among women with epithelial ovarian cancer, with a stronger association among Black women.

    FDA approves combo for ESR1-mutated breast cancer

    In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.